Biofrontera (BFRI) Reports Prelim Q2 Revenue of $5.7M-$5.9M

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. ANT
3. SPY
4. META
5. FFAI
6. FFR
7. FICO
8. CART
9. LLY
10. TSLA

Go back to Biofrontera (BFRI) Reports Prelim Q2 Revenue of $5.7M-$5.9M

Biofrontera Inc. Announces Preliminary Second Quarter Revenues are Up 26% to 31%

July 13, 2023 9:02 AM EDT

Management Reaffirms Full-Year 2023 Revenue Growth of at least 25% over Prior Year

WOBURN, MA / ACCESSWIRE / July 13, 2023 / Biofrontera Inc. (Nasdaq: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced preliminary unaudited revenues for the three months ended June 30, 2023.

Revenues for the second quarter of 2023 are anticipated to be in the range of approximately $5.7 million to $5.9 million, an increase of approximately 26% to 31% compared with the second quarter of 2022. As a result, revenues for the first half of 2023 are anticipated to be in the... More